{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T10:05:26Z","timestamp":1789639526111,"version":"4.0.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To assess the effect of gestational age\u2013based dosing of unfractionated heparin (UFH) compared with standard dosing of UFH for thromboprophylaxis on an elevated serum activated partial thromboplastin time (aPTT) during prolonged antepartum hospitalizations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>This was a randomized trial of pregnant persons who were admitted in the antepartum period for at least 72 hours. Participants were randomly allocated to the standard dose of UFH (5,000 units subcutaneously every 12 hours) or the gestational age\u2013based dose of UFH (first trimester [less than 14 weeks]: 5,000 units subcutaneously every 12 hours; second trimester [14\u201327 6\/7 weeks]: 7,500 units subcutaneously every 12 hours; third trimester (28 weeks or more): 10,000 units subcutaneously every 12 hours). The primary outcome was the proportion of antepartum patients who had an elevated serum aPTT value above the normal range (more than 36.2 seconds) 6 hours after an UFH dose. Secondary outcomes included the development of venous thromboembolism (VTE) and reported side effects of heparin administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      Between December 15, 2020, and April 1, 2022, 97 patients with antepartum hospitalizations were screened and 46 were randomized: 22 allocated to standard dosing and 24 allocated to gestational age\u2013based dosing of UFH. A significantly greater proportion of antepartum patients who received gestational age\u2013based dosing had an abnormal elevation in aPTT compared with those who received standard dosing (33.3% vs 4.8%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =.02). Gestational age\u2013based dosing resulted in higher maximum [interquartile range] aPTT (30.4 [27.4, 37.5] vs 26.6 [23.0, 29.6],\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =.01) and anti-Xa levels (0.09 [0.09, 0.11] vs 0.09 [0.09, 0.09],\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =.04). There was no significant difference in VTE between groups (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =.47).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>Gestational age\u2013based dosing of UFH for thromboprophylaxis of antepartum hospitalizations was associated with significantly increased rates of elevated coagulation parameters compared with standard fixed dosing. This study suggests a need for close monitoring if higher doses of UFH during pregnancy are used later in gestation. The efficacy of gestational age\u2013based dosing compared with standard dosing for UFH to prevent thromboembolic events remains an area for future investigation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CLINICAL TRIAL REGISTRATION:<\/jats:title>\n                    <jats:p>ClinicalTrials.gov, NCT04635839.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/aog.0000000000005599","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T17:00:25Z","timestamp":1715706025000},"page":"118-125","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Prophylactic Unfractionated Heparin in Antepartum Hospitalizations"],"prefix":"10.1097","volume":"144","author":[{"given":"Thalia","family":"Mok","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anissa V.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorna","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irving","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristianna","family":"Vallera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil S.","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,5,14]]},"reference":[{"key":"R1-20260826","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S0140-6736(06)68397-9","article-title":"WHO analysis of causes of maternal death: a systematic review","volume":"367","author":"Khan","year":"2006","journal-title":"Lancet"},{"key":"R2-20260826","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/AOG.0000000000000564","article-title":"Pregnancy-related mortality in the United States, 2006-2010","volume":"125","author":"Creanga","year":"2015","journal-title":"Obstet Gynecol"},{"key":"R3-20260826","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.ajog.2005.11.008","article-title":"Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality","volume":"194","author":"James","year":"2006","journal-title":"Am J Obstet Gynecol"},{"key":"R4-20260826","doi-asserted-by":"crossref","first-page":"f6099","DOI":"10.1136\/bmj.f6099","article-title":"Risk of first venous thromboembolism in pregnant women in hospital: population based cohort study from England","volume":"347","author":"Abdul Sultan","year":"2013","journal-title":"BMJ"},{"key":"R5-20260826","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ajog.2021.05.004","article-title":"Expert review: prevention of obstetrical venous thromboembolism","volume":"225","author":"Friedman","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"R7-20260826","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1055\/s-0037-1612949","article-title":"The APTT response of pregnant plasma to unfractionated heparin","volume":"87","author":"Young","year":"2002","journal-title":"Thromb Haemost"},{"key":"R8-20260826","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/0002-9378(95)91362-9","article-title":"Pharmacokinetics and pharmacodynamics of subcutaneous heparin during the early third trimester of pregnancy","volume":"173","author":"Brancazio","year":"1995","journal-title":"Am J Obstet Gynecol"},{"key":"R9-20260826","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/0002-9378(95)90443-3","article-title":"Heparin levels to guide thromboembolism prophylaxis during pregnancy","volume":"173","author":"Barbour","year":"1995","journal-title":"Am J Obstet Gynecol"},{"key":"R10-20260826","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/AOG.0000000000002706","article-title":"Thromboembolism in pregnancy. ACOG Practice Bulletin No. 196. American College of Obstetricians and Gynecologists","volume":"132","year":"2018","journal-title":"Obstet Gynecol"},{"key":"R11-20260826","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.amjmed.2019.03.021","article-title":"Reasons for differences in the incidence of venous thromboembolism in Black versus White Americans","volume":"132","author":"Folsom","year":"2019","journal-title":"Am J Med"},{"key":"R12-20260826","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJM197303152881103","article-title":"Small subcutaneous doses of heparin in prevention of venous thrombosis","volume":"288","author":"Gallus","year":"1973","journal-title":"New Engl J Med"},{"key":"R13-20260826","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/AAP.0000000000000763","article-title":"Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional anesthesia and pain medicine evidence-based guidelines (fourth edition)","volume":"43","author":"Horlocker","year":"2018","journal-title":"Reg Anesth Pain Med"},{"key":"R14-20260826","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1213\/ANE.0000000000002530","article-title":"Perinatology consensus statement on the anesthetic management of pregnant and postpartum women receiving thromboprophylaxis or higher dose anticoagulants","volume":"126","author":"Leffer","year":"2018","journal-title":"Anesth Analg"},{"key":"R16-20260826","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1097\/AOG.0000000000001579","article-title":"National partnership for maternal safety consensus bundle on venous thromboembolism","volume":"128","author":"D\u02bcAlton","year":"2016","journal-title":"Obstet Gynecol"},{"key":"R17-20260826","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/AOG.0000000000001656","article-title":"Pharmacologic thromboprophylaxis in obstetrics: broader use demands better data","volume":"128","author":"Sibai","year":"2016","journal-title":"Obstet Gynecol"},{"key":"R18-20260826","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/clpt.2008.73","article-title":"Changes in enoxaparin pharmacokinetics during pregnancy and implications for antithrombotic therapeutic strategy","volume":"84","author":"Lebaudy","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"R19-20260826","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1177\/1074248414524302","article-title":"Monitoring of anti-Xa in pregnant patients with mechanical prosthetic valves receiving low-molecular weight heparin: peak or trough levels?","volume":"19","author":"Goland","year":"2014","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"R20-20260826","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1177\/1753495X16659401","article-title":"Increased unfractionated heparin requirements with decreasing body mass index in pregnancy","volume":"9","author":"Patil","year":"2016","journal-title":"Obstet Med"},{"key":"R21-20260826","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/AOG.0000000000004521","article-title":"Evaluation of a risk-stratified, heparin-based, obstetric thromboprophylaxis protocol","volume":"138","author":"Lu","year":"2021","journal-title":"Obstet Gynecol"},{"key":"R22-20260826","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/S0140-6736(22)02128-6","article-title":"Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial","volume":"400","author":"Bistervels","year":"2022","journal-title":"Lancet"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000005599","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T11:00:50Z","timestamp":1787742050000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000005599"}},"subtitle":["A Randomized Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2024,5,14]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000005599","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,14]]},"assertion":[{"value":"2024-01-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}